Dyslipidemia in diabetic nephropathy

Renal Replacement Therapy

Volumn 2, Issue 1, 2016, Pages

  Kawanami, Daiji ^a   Matoba, Keiichiro ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease; Diabetic nephropathy; Dyslipidemia; Rho kinase; Statin

Indexed keywords

EID: 85032590955     PISSN: None     EISSN: 20591381     Source Type: Journal    
DOI: 10.1186/s41100-016-0028-0     Document Type: Review

References (87)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225-32. doi: 10.1046/j.1523-1755.2003.00712.x.
2. Rutledge JC, Ng KF, Aung HH, Wilson DW. Role of triglyceride-rich lipoproteins in diabetic nephropathy. Nat Rev Nephrol. 2010;6(6):361-70. doi: 10.1038/nrneph.2010.59.
3. Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol. 2014;18(2):206-9. doi: 10.1007/s10157-013-0880-y.
4. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management. Drugs. 2013;73(4):327-39. doi: 10.1007/s40265-013-0023-5.
5. Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, Chen RS, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263-9. doi: 10.1016/j.diabres.2005.03.032.
6. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex. Diabetes Care. 1997;20(11):1683-7. http://care.diabetesjournals.org/content/20/11/1683.
7. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. Am Heart J. 1985;110(5):1100-7.
8. Parish S, Offer A, Clarke R, Hopewell JC, Hill MR, Otvos JD, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012;125(20):2469-78. doi: 10.1161/CIRCULATIONAHA.111.073684.
9. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150-9. doi: 10.1038/ncpendmet1066.
10. Pollare T, Vessby B, Lithell H. Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb. 1991;11(5):1192-203.
11. Hayashi T, Hirano T, Taira T, Tokuno A, Mori Y, Koba S, et al. Remarkable increase of apolipoprotein B48 level in diabetic patients with end-stage renal disease. Atherosclerosis. 2008;197(1):154-8. doi: 10.1016/j.atherosclerosis.2007.03.015.
12. Svensson M, Eriksson JW. Insulin resistance in diabetic nephropathy-cause or consequence? Diabetes Metab Res Rev. 2006;22(5):401-10. doi: 10.1002/dmrr.648.
13. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies. Diabetes Metab. 2000;26(4):254-64.
14. Bouillet B, Gautier T, Blache D, Pais de Barros JP, Duvillard L, Petit JM, et al. Glycation of apolipoprotein C1 impairs its CETP inhibitory property: Pathophysiological relevance in patients with type 1 and type 2 diabetes. Diabetes Care. 2014;37(4):1148-56. doi: 10.2337/dc13-1467.
15. Kimura H, Miyazaki R, Imura T, Masunaga S, Suzuki S, Gejyo F, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64(5):1829-37. doi: 10.1046/j.1523-1755.2003.00285.x.
16. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):F262-72. doi: 10.1152/ajprenal.00099.2005.
17. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoprotein metabolism. Obesity. 2008;16(6):1152-60. doi: 10.1038/oby.2008.202.
18. Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 2004;53(3):513-20.
19. Wellmann KF, Volk BW. Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits. II. Long term studies. Lab Invest. 1971;24(2):144-55.
20. Utsunomiya K, Ohta H, Kurata H, Tajima N, Isogai Y. The effect of macrophage colony-stimulating factor (M-CSF) on the progression of lipid-induced nephrotoxicity in diabetic nephropathy. J Diabetes Complicat. 1995;9(4):292-5.
21. Hammad SM, Hazen-Martin DJ, Sohn M, Eldridge L, Powell-Braxton L, Won W, et al. Nephropathy in a hypercholesterolemic mouse model with streptozotocin-induced diabetes. Kidney Blood Press Res. 2003;26(5-6):351-61. doi: 10.1159/000073942.
22. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33(3):667-72.
23. Wheeler DC, Fernando RL, Gillett MP, Zaruba J, Persaud J, Kingstone D, et al. Characterisation of the binding of low-density lipoproteins to cultured rat mesangial cells. Nephrol Dial Transplant. 1991;6(10):701-8.
24. Grone HJ, Walli AK, Grone E, Kramer A, Clemens MR, Seidel D. Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. Kidney Int. 1990;37(6):1449-59.
25. Quaschning T, Koniger M, Kramer-Guth A, Greiber S, Pavenstadt H, Nauck M, et al. Receptor-mediated lipoprotein uptake by human glomerular cells: Comparison with skin fibroblasts and HepG2 cells. Nephrol Dial Transplant. 1997;12(12):2528-36.
26. Kramer A, Nauck M, Pavenstadt H, Schwedler S, Wieland H, Schollmeyer P, et al. Receptor-mediated uptake of IDL and LDL from nephrotic patients by glomerular epithelial cells. Kidney Int. 1993;44(6):1341-51.
27. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999;71:S51-3.
28. Eiselein L, Wilson DW, Lame MW, Rutledge JC. Lipolysis products from triglyceride-rich lipoproteins increase endothelial permeability, perturb zonula occludens-1 and F-actin, and induce apoptosis. Am J Physiol Heart Circ Physiol. 2007;292(6):H2745-53. doi: 10.1152/ajpheart.00686.2006.
29. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. Am J Kidney Dis. 1993;22(1):72-82.
30. Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21(2):79-85. doi: 10.1016/j.numecd.2010.10.002.
31. Kamanna VS, Pai R, Roh DD, Kirschenbaum MA. Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation, and proliferation. Lab Invest. 1996;74(6):1067-79.
32. Ishigaki N, Yamamoto T, Shimizu Y, Kobayashi K, Yatoh S, Sone H, et al. Involvement of glomerular SREBP-1c in diabetic nephropathy. Biochem Biophys Res Commun. 2007;364(3):502-8. doi: 10.1016/j.bbrc.2007.10.038.
33. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, et al. Exacerbation of diabetic nephropathy by hyperlipidaemia is mediated by Toll-like receptor 4 in mice. Diabetologia. 2012;55(8):2256-66. doi: 10.1007/s00125-012-2578-1.
34. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331-40.
35. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The endothelial glycocalyx: A potential barrier between health and vascular disease. Curr Opin Lipidol. 2005;16(5):507-11.
36. Nieuwdorp M, Meuwese MC, Mooij HL, Ince C, Broekhuizen LN, Kastelein JJ, et al. Measuring endothelial glycocalyx dimensions in humans: A potential novel tool to monitor vascular vulnerability. J Appl Physiol. 2008;104(3):845-52. doi: 10.1152/japplphysiol.00440.2007.
37. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM. Receptor for advanced glycation end products: Fundamental roles in the inflammatory response: Winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci. 2008;1126:7-13. doi: 10.1196/annals.1433.056.
38. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Mazzitelli G, et al. Advanced lipoxidation end-products mediate lipid-induced glomerular injury: Role of receptor-mediated mechanisms. J Pathol. 2009;218(3):360-9. doi: 10.1002/path.2536.
39. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: The effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117-24.
40. Koya D, Campese VM. Statin use in patients with diabetes and kidney disease: The Japanese experience. J Atheroscler Thromb. 2013;20(5):407-24.
41. Sasaki T, Kurata H, Nomura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med. 1990;29(2):156-63.
42. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: A subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004;43(4):589-99.
43. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol. 2005;16(12):3748-54. doi: 10.1681/ASN.2005070779.
44. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets (TNT) study. Clin J Am Soc Nephrol. 2007;2(6):1131-9. doi: 10.2215/CJN.04371206.
45. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: An analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis. 2009;54(5):810-9. doi: 10.1053/j.ajkd.2009.03.022.
46. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-forming kinases (ROCKs): Potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci. 2011;32(3):167-73. doi: 10.1016/j.tips.2010.12.006.
47. Fujisawa K, Fujita A, Ishizaki T, Saito Y, Narumiya S. Identification of the Rho-binding domain of p160ROCK, a Rho-associated coiled-coil containing protein kinase. J Biol Chem. 1996;271(38):23022-8.
48. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2005;25(8):1697-703. doi: 10.1161/01.ATV.0000172689.53992.25.
49. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: Turning on the switch. Genes Dev. 2002;16(13):1587-609. doi: 10.1101/gad.1003302.
50. Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2006;27(2):97-104. doi: 10.1016/j.tips.2005.12.002.
51. Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, et al. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;568(1-3):242-7. doi: 10.1016/j.ejphar.2007.04.011.
52. Isoe T, Makino Y, Mizumoto K, Sakagami H, Fujita Y, Honjo J, et al. High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein. Kidney Int. 2010;78(1):48-59. doi: 10.1038/ki.2010.99.
53. Matoba K, Kawanami D, Okada R, Tsukamoto M, Kinoshita J, Ito T, et al. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1alpha. Kidney Int. 2013;84(3):545-54. doi: 10.1038/ki.2013.130.
54. Matoba K, Kawanami D, Ishizawa S, Kanazawa Y, Yokota T, Utsunomiya K. Rho-kinase mediates TNF-alpha-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells. Biochem Biophys Res Commun. 2010;402(4):725-30. doi: 10.1016/j.bbrc.2010.10.093.
55. Matoba K, Kawanami D, Tsukamoto M, Kinoshita J, Ito T, Ishizawa S, et al. Rho-kinase regulation of TNF-alpha-induced nuclear translocation of NF-kappaB RelA/p65 and M-CSF expression via p38 MAPK in mesangial cells. Am J Physiol Renal Physiol. 2014;307(5):F571-80. doi: 10.1152/ajprenal.00113.2014.
56. Yokota T, Utsunomiya K, Taniguchi K, Gojo A, Kurata H, Tajima N. Involvement of the Rho/Rho kinase signaling pathway in platelet-derived growth factor BB-induced vascular endothelial growth factor expression in diabetic rat retina. Jpn J Ophthalmol. 2007;51(6):424-30. doi: 10.1007/s10384-007-0471-0.
57. Kanazawa Y, Takahashi-Fujigasaki J, Ishizawa S, Takabayashi N, Ishibashi K, Matoba K, et al. The Rho-kinase inhibitor fasudil restores normal motor nerve conduction velocity in diabetic rats by assuring the proper localization of adhesion-related molecules in myelinating Schwann cells. Exp Neurol. 2013;247:438-46. doi: 10.1016/j.expneurol.2013.01.012.
58. Kawanami D, Matoba K, Kanazawa Y, Ishizawa S, Yokota T, Utsunomiya K. Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-kappaB signaling pathway activation in vascular endothelial cells. Biochem Biophys Res Commun. 2011;411(4):798-803. doi: 10.1016/j.bbrc.2011.07.031.
59. Kushiyama T, Oda T, Yamamoto K, Higashi K, Watanabe A, Takechi H, et al. Protective effects of Rho kinase inhibitor fasudil on rats with chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(11):F1325-34. doi: 10.1152/ajprenal.00447.2012.
60. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.
61. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54(2):280-90. doi: 10.1007/s00125-010-1951-1.
62. Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. doi: 10.1056/NEJMoa1001282.
63. Mychaleckyj JC, Craven T, Nayak U, Buse J, Crouse JR, Elam M, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care. 2012;35(5):1008-14. doi: 10.2337/dc11-1811.
64. Ansquer JC, Dalton RN, Causse E, Crimet D, Le Malicot K, Foucher C. Effect of fenofibrate on kidney function: A 6-week randomized crossover trial in healthy people. Am J Kidney Dis. 2008;51(6):904-13. doi: 10.1053/j.ajkd.2008.01.014.
65. Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet. 2001;358(9275):39-40. doi: 10.1016/S0140-6736(00)05271-5.
66. Forsblom C, Hiukka A, Leinonen ES, Sundvall J, Groop PH, Taskinen MR. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: The FIELD Helsinki substudy. Diabetes Care. 2010;33(2):215-20. doi: 10.2337/dc09-0621.
67. Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001;55(1):39-44.
68. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002;92(3):536-41.
69. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: The J-BENEFIT study. Cardiovasc Diabetol. 2012;11:29. doi: 10.1186/1475-2840-11-29.
70. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab. 2004;89(2):463-78. doi: 10.1210/jc.2003-030723.
71. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet. 2011;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3.
72. Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25(8):1825-33. doi: 10.1681/ASN.2013090965.
73. Hagiwara S, Makita Y, Gu L, Tanimoto M, Zhang M, Nakamura S, et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant. 2006;21(3):605-15. doi: 10.1093/ndt/gfi208.
74. Zhang M, Hagiwara S, Matsumoto M, Gu L, Tanimoto M, Nakamura S, et al. Effects of eicosapentaenoic acid on the early stage of type 2 diabetic nephropathy in KKA(y)/Ta mice: Involvement of anti-inflammation and antioxidative stress. Metabolism. 2006;55(12):1590-8. doi: 10.1016/j.metabol.2006.07.019.
75. Shapiro H, Theilla M, Attal-Singer J, Singer P. Effects of polyunsaturated fatty acid consumption in diabetic nephropathy. Nat Rev Nephrol. 2011;7(2):110-21. doi: 10.1038/nrneph.2010.156.
76. Lee CC, Sharp SJ, Wexler DJ, Adler AI. Dietary intake of eicosapentaenoic and docosahexaenoic acid and diabetic nephropathy: Cohort analysis of the diabetes control and complications trial. Diabetes Care. 2010;33(7):1454-6. doi: 10.2337/dc09-2245.
77. Lee CT, Adler AI, Forouhi NG, Luben R, Welch A, Khaw KT, et al. Cross-sectional association between fish consumption and albuminuria: The European Prospective Investigation of Cancer-Norfolk study. Am J Kidney Dis. 2008;52(5):876-86. doi: 10.1053/j.ajkd.2008.02.307.
78. Haines AP, Sanders TA, Imeson JD, Mahler RF, Martin J, Mistry M, et al. Effects of a fish oil supplement on platelet function, haemostatic variables and albuminuria in insulin-dependent diabetics. Thromb Res. 1986;43(6):643-55.
79. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T. Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med. 1989;321(23):1572-7. doi: 10.1056/NEJM198912073212304.
80. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S. Reduction in microalbuminuria in diabetics by eicosapentaenoic acid ethyl ester. Lipids. 1990;25(9):541-5.
81. Shimizu H, Ohtani K, Tanaka Y, Sato N, Mori M, Shimomura Y. Long-term effect of eicosapentaenoic acid ethyl (EPA-E) on albuminuria of non-insulin dependent diabetic patients. Diabetes Res Clin Pract. 1995;28(1):35-40.
82. Wallin A, Di Giuseppe D, Orsini N, Patel PS, Forouhi NG, Wolk A. Fish consumption, dietary long-chain n-3 fatty acids, and risk of type 2 diabetes: Systematic review and meta-analysis of prospective studies. Diabetes Care. 2012;35(4):918-29. doi: 10.2337/dc11-1631.
83. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645-51. doi: 10.1136/bmj.39472.580984.AE.
84. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238-48.
85. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395-407. doi: 10.1056/NEJMoa0810177.
86. Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, et al. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011;22(7):1335-41. doi: 10.1681/ASN.2010090987.
87. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et al. Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney Int. 2011;79(9):997-1004. doi: 10.1038/ki.2010.524.